Icon of a globe with an arrow circling around it.

Value-Added Service

Real-World Data (RWD) Collection

How is Real World Data Collection Integrated into Access Programs?

Real‑world data collection must be incorporated into access programs in a way that does not inhibit patient access. This requires data collection that is focused, justifiable, of minimal burden, aligned with routine treatment and country‑specific regulatory requirements. 

Abstract geometric artwork with colored triangles and rectangles in black, gray, white, and green.

At Tanner Pharma, we manage RWD collection through a practical, compliance‑driven approach.

Data requirements are tailored by country and site to reflect regulatory expectations and participation realities, ensuring meaningful data is captured without delaying treatment or creating access barriers.

What Operational Factors Shape RWD Collection?

  • Spontaneous safety event capture is standard in access programs

  • Baseline patient data is typically collected before first shipment

  • Data collection is often aligned with shipment cadence

  • Efficacy data cannot be mandated outside a protocol

  • Site participation may require compensation

Tanner’s Strategic Recommendations

  • Keep data collection focused, valuable and justified

  • Sponsors cannot insist on RWD collection as a prerequisite for a patient

  • Anticipate variable HCP and patient participation

  • Consider compensating sites if data collection is critical

  • Optimize datasets by country or site, focusing on where the data is most valuable

  • Confirm regulatory agreement where required

  • Engage HCPs early in planning

Our Approach to Real-World Data (RWD) Collection

Keep data collection aligned with existing workflows

Maintain regulatory and pharmacovigilance compliance

Focus on meaningful and practical datasets

Protect patient access and treatment timelines

Explore a Practical Approach to RWD Collection